Scarica l'app Stockscreener
4.10
0.00%
0.00
Precedente Chiudi:
$4.10
Aprire:
$4.11
Volume 24 ore:
75,028
Relative Volume:
0.57
Capitalizzazione di mercato:
$13.17M
Reddito:
-
Utile/perdita netta:
$-21.21M
Rapporto P/E:
-2.426
EPS:
-1.69
Flusso di cassa netto:
$-16.86M
1 W Prestazione:
-2.61%
1M Prestazione:
-8.48%
6M Prestazione:
-44.88%
1 anno Prestazione:
-84.11%
Intervallo 1D:
$4.10
$4.27
Intervallo di 1 settimana:
$4.00
$4.32
Portata 52W:
$1.8001
$152.40
Cingulate Inc Stock (CING) Company Profile
Nome
Cingulate Inc
Settore
Industria
Telefono
(913) 942-2300
Indirizzo
1901 W. 47TH PLACE, KANSAS CITY
Confronta CING con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CING
Cingulate Inc
|
4.10 | 13.17M | 0 | -21.21M | -16.86M | -32.60 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Cingulate Inc Stock (CING) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2023-12-22 | Downgrade | Laidlaw | Buy → Hold |
Cingulate Inc Borsa (CING) Ultime notizie
Cingulate (NASDAQ:CING) Upgraded at Maxim Group - Defense World
U.S. Stock market top gainers: Binah Capital Group gains +107.02%, Aligos Therapeutics surges by 42.84% in mid day trading - Business Upturn
Cingulate Inc. Announces Third Quarter Financial Results and Clinical Update - Defense World
Cingulate Inc (CING) Quarterly 10-Q Report - Quartz
CINGCingulate Inc. Latest Stock News & Market Updates - StockTitan
Cingulate reports Q3 net loss $3.2M vs. $5.98M last year - TipRanks
Cingulate Reports Third Quarter 2024 Financial - GlobeNewswire
Cingulate Reports Third Quarter 2024 Financial Results Reflecting $19.5 Million Increase in Working Capital to Advance ADHD Drug to Market - StockTitan
Cingulate Slashes Net Loss 46%, Secures $12.5M Funding Boost Amid European Patent Wins | CINGW Stock News - StockTitan
Cingulate's Shane Schaffer Joins Cast of Nationally Syndicated Big Biz Show - The Manila Times
Cingulate’s Shane Schaffer Joins Cast of Nationally Syndicated Big Biz Show - GlobeNewswire
Cingulate secures funding to extend operations into Q2 2025 By Investing.com - Investing.com South Africa
SEC Form 424B3 filed by Cingulate Inc. - Quantisnow
Cingulate secures funding to extend operations into Q2 2025 - Investing.com India
Cingulate Inc Files for 1.5M Share Offering by Selling Stockholders - Investing.com Canada
Cingulate Inc. CEO faces domestic battery charge - Investing.com India
Cingulate Inc. CEO faces domestic battery charge By Investing.com - Investing.com South Africa
KC-area public company CEO faces charges for aggravated domestic battery - Kansas City Business Journal
Cingulate files to sell 1.5M shares of common stock for holders - MSN
Will Ciena's New 1.6 Tb/s Coherent Pluggable Solution Drive Top Line? - Zacks Investment Research
Concentrix Corp (CNXC) Q3 2024: Everything You Need to Know Ahea - GuruFocus.com
Cettire shares skyrocket - Finance News Network
Cettire gets auditor’s tick of approval, adding $247m to valuation - The Australian Financial Review
Stock of the day: Cettire - IG
Ciena Stock Goes to Buy From Sell at Citi. Here’s Why. - Barron's
Why Ciena Stock Popped 5% on Monday - The Motley Fool
Double-Upgrade Pushes Ciena Stock Near Record Highs - Schaeffers Research
Citi upgrades Ciena, shares rise in pre-market trade By Investing.com - Investing.com Canada
9 Analysts Assess Ciena: What You Need To Know - Benzinga
Ciena Unveils 1.6 Tb/s Coherent Pluggable Solution for Hyperscale Cloud Providers' Capacity Surge - Marketscreener.com
Ciena's stock rises after Citi double upgrades to Buy (NYSE:CIEN) - Seeking Alpha
Citi sees growth potential for Ciena stock as inventory challenges ease - Investing.com Australia
Ciena Co. (NYSE:CIEN) Shares Sold by Thrivent Financial for Lutherans - Defense World
KC-area pharmaceutical company starts its last trial before seeking FDA approval - The Business Journals
CING’s Market Whiplash: -94.12% YTD Decline, 192.68% Rise in 30 Days - The InvestChronicle
Cingulate Inc (CING)’s stock decline to 5.40 per share - US Post News
Where are the Opportunities in (CING) - Stock Traders Daily
Cingulate Inc (CING) Stock: A Year of Stock Market Dynamics - The InvestChronicle
Cingulate Inc: Executive Pay Restored, Funding Up, FDA Study Launched - TipRanks
Cingulate initiates final study for ADHD asset CTx-1301 - TipRanks
Cingulate Initiates Final Study for Lead ADHD Asset CTx-1301 - GlobeNewswire
Market Insights: Cingulate Inc (CING)’s Notable Gain of 19.45, Closing at 6.51 - The Dwinnex
Cingulate regains Nasdaq compliance with bid price - Investing.com
Cingulate Shares Are Trading By More Than 200% Friday: What You Need To Know - MSN
Stocks of Cingulate Inc (CING) are poised to climb above their peers - SETE News
September 04, 2024 09:00 AM, Eastern - Nasdaq
Was there any good news for Cingulate Inc (CING) stock in the last session? - US Post News
Cingulate Inc. expands at-the-market offering by $3.87 million - Investing.com
Financial Health Report: Cingulate Inc (CING)’s Ratios Tell a Tale - The Dwinnex
CING’s 2023 Market Dance: Down -91.41% – Time to Invest? - The InvestChronicle
What's Going On With Cingulate Shares Recently? - MSN
Cingulate Inc Azioni (CING) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.88%
2.65%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):